Sample paper formatted on SciSpace - SciSpace

This content is only for preview purposes. The original open access content can be found here.

Open Access

Diabetic Medicine — Template for authors

Publisher: Wiley

Your data will always be in your control. Learn more

Get started with a free account

— or sign up using email —

See how it works

Guideline source

Categories	Rank	Trend in last 3 yrs
Internal Medicine	#23 of 121	up by 2 ranks
Endocrinology, Diabetes and Metabolism	#50 of 219	up by 4 ranks
Endocrinology	#37 of 117	up by 2 ranks

Journal quality:

High

Last 4 years overview: 833 Published Papers | 5116 Citations

Indexed in: Scopus

Last updated: 09/07/2020

Related journals

Insights

General info

Related Journals

Open Access

Acta Diabetologica

Springer

Quality:

High

CiteRatio: 6.0

SJR: 1.141

SNIP: 1.158

Open Access

Journal of Diabetes and its Complications

Elsevier

Quality:

High

CiteRatio: 5.4

SJR: 1.022

SNIP: 1.091

Open Access

Diabetes Research and Clinical Practice

Elsevier

Quality:

High

CiteRatio: 7.7

SJR: 1.605

SNIP: 2.01

Open Access

Recommended

Diabetes, Obesity and Metabolism

Wiley

Quality:

High

CiteRatio: 10.9

SJR: 2.445

SNIP: 1.479

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.083

1% from 2018

Impact factor for Diabetic Medicine from 2016 - 2019
Year	Value
2019	3.083
2018	3.107
2017	3.132
2016	3.054

Graph view

6.1

CiteRatio for Diabetic Medicine from 2016 - 2020
Year	Value
2020	6.1
2019	6.1
2018	6.1
2017	5.8
2016	6.4

Graph view

Insights

Impact factor of this journal has decreased by 1% in last year.
This journal’s impact factor is in the top 10 percentile category.

Insights

This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.474

2% from 2019

SJR for Diabetic Medicine from 2016 - 2020
Year	Value
2020	1.474
2019	1.502
2018	1.515
2017	1.628
2016	1.559

Graph view

1.473

21% from 2019

SNIP for Diabetic Medicine from 2016 - 2020
Year	Value
2020	1.473
2019	1.22
2018	1.269
2017	1.238
2016	1.406

Graph view

Insights

SJR of this journal has decreased by 2% in last years.
This journal’s SJR is in the top 10 percentile category.

Insights

SNIP of this journal has increased by 21% in last years.
This journal’s SNIP is in the top 10 percentile category.

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Wiley

Diabetic Medicine

Diabetic Medicine, one of the leading clinical diabetes journals in the world, publishes comprehensive reviews and original articles on clinical research and practice in diabetes. Issues also regularly include case reports, editorials, comment, news and correspondence. All material is peer-reviewed as the journal seeks to provide a forum for the exchange of information between clinicians and researchers worldwide and all health professionals responsible for the care of people with diabetes. Read Less

Medicine

Last updated on	09 Jul 2020
ISSN	0742-3071
Impact Factor	High - 1.342
Acceptance Rate	28%
Open Access	Yes
Sherpa RoMEO Archiving Policy	Yellow
Plagiarism Check	Available via Turnitin
Endnote Style	Download Available
Bibliography Name	apa
Citation Type	Numbered [25]
Bibliography Example	Beenakker, C.W.J. (2006) Specular andreev reflection in graphene.Phys. Rev. Lett., 97 (6), 067 007. URL 10.1103/PhysRevLett.97.067007.

Top papers written in this journal

Journal Article • DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S •

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

K. G. M. M. Alberti¹, Paul Zimmet •

01 Jul 1998 - Diabetic Medicine

Abstract:

The classification of diabetes mellitus and the tests used for its diagnosis were brought into order by the National Diabetes Data Group of the USA and the second World Health Organization Expert Committee on Diabetes Mellitus in 1979 and 1980. Apart from minor modifications by WHO in 1985, little has been changed since that ... The classification of diabetes mellitus and the tests used for its diagnosis were brought into order by the National Diabetes Data Group of the USA and the second World Health Organization Expert Committee on Diabetes Mellitus in 1979 and 1980. Apart from minor modifications by WHO in 1985, little has been changed since that time. There is however considerable new knowledge regarding the aetiology of different forms of diabetes as well as more information on the predictive value of different blood glucose values for the complications of diabetes. A WHO Consultation has therefore taken place in parallel with a report by an American Diabetes Association Expert Committee to re-examine diagnostic criteria and classification. The present document includes the conclusions of the former and is intended for wide distribution and discussion before final proposals are submitted to WHO for approval. The main changes proposed are as follows. The diagnostic fasting plasma (blood) glucose value has been lowered to > or =7.0 mmol l(-1) (6.1 mmol l(-1)). Impaired Glucose Tolerance (IGT) is changed to allow for the new fasting level. A new category of Impaired Fasting Glycaemia (IFG) is proposed to encompass values which are above normal but below the diagnostic cut-off for diabetes (plasma > or =6.1 to or =5.6 to <6.1 mmol l(-1)). Gestational Diabetes Mellitus (GDM) now includes gestational impaired glucose tolerance as well as the previous GDM. The classification defines both process and stage of the disease. The processes include Type 1, autoimmune and non-autoimmune, with beta-cell destruction; Type 2 with varying degrees of insulin resistance and insulin hyposecretion; Gestational Diabetes Mellitus; and Other Types where the cause is known (e.g. MODY, endocrinopathies). It is anticipated that this group will expand as causes of Type 2 become known. Stages range from normoglycaemia to insulin required for survival. It is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements. read more

Topics:

Impaired fasting glucose (71%)71% related to the paper, Impaired glucose tolerance (67%)67% related to the paper, Ketosis-prone diabetes (65%)65% related to the paper,

15,167 Citations

Open access • Journal Article • DOI: 10.1111/J.1464-5491.2006.01858.X •

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

K. G. M. M. Alberti¹, Paul Zimmet¹, •

01 May 2006 - Diabetic Medicine

Abstract:

469 Abstract Aims To establish a unified working diagnostic tool for the metabolic syndrome (MetS) that is convenient to use in clinical practice and that can be used world- wide so that data from different countries can be compared. An additional aim was to highlight areas where more research into the MetS is needed. Partici... 469 Abstract Aims To establish a unified working diagnostic tool for the metabolic syndrome (MetS) that is convenient to use in clinical practice and that can be used world- wide so that data from different countries can be compared. An additional aim was to highlight areas where more research into the MetS is needed. Participants The International Diabetes Federation (IDF) convened a workshop held 12-14 May 2004 in London, UK. The 21 participants included experts in the fields of diabetes, public health, epidemiology, lipidology, genetics, metabolism, nutrition and cardiology. There were participants from each of the five con- tinents as well as from the World Health Organization (WHO) and the National Cholesterol Education Program—Third Adult Treatment Panel (ATP III). The workshop was sponsored by an educational grant from AstraZeneca Pharmaceuticals. Consensus process The consensus statement emerged following detailed discussions at the IDF workshop. After the workshop, a writing group produced a consensus statement which was reviewed and approved by all participants. Conclusions The IDF has produced a new set of criteria for use both epidemio- logically and in clinical practice world-wide with the aim of identifying people with the MetS to clarify the nature of the syndrome and to focus therapeutic strategies to reduce the long-term risk of cardiovascular disease. Guidance is included on how to compensate for differences in waist circumference and in regional adipose tissue distribution between different populations. The IDF has also produced recommendations for additional criteria that should be included when studying the MetS for research purposes. Finally, the IDF has identified areas where more studies are currently needed; these include research into the aetiology of the syndrome. Diabet. Med. 23, 469-480 (2006) read more

View PDF

5,612 Citations

Journal Article • DOI: 10.1046/J.1464-5491.1999.00059.X •

Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)

Beverley Balkau, Marie-Aline Charles

01 May 1999 - Diabetic Medicine

Abstract:

The recent provisional report on the de®nition, diagnosis and classi®cation from the WHO described `the metabolic syndrome' as a `major classi®cation, diagnostic and therapeutic challenge'±andweagree[1].Ade®nitionissorelyneededforthe syndrome, as to date each publication describing the syndrome usesitsownde®nitionofacomponent... The recent provisional report on the de®nition, diagnosis and classi®cation from the WHO described `the metabolic syndrome' as a `major classi®cation, diagnostic and therapeutic challenge'±andweagree[1].Ade®nitionissorelyneededforthe syndrome, as to date each publication describing the syndrome usesitsownde®nitionofacomponent,anditsowncombination and number of components to constitute the syndrome. If identi®cation of the syndrome is aimed at prevention or a speci®c treatment of insulin resistance, a clear de®nition needs to be provided, and the risk associated with the syndrome evaluated in prospective studies. Our basic premise for the de®nition is that it is a syndrome of mild anomalies which, in combination, increase cardiovascular risk. We suggest that because the syndrome includes nonmetabolic features, a more appropriate name would be the `insulin resistance syndrome'. We also challenge the de®nition proposed,namely,atleastoneofimpairedglucoseregulationor insulin resistance and two or more of raised arterial pressure, dyslipidaemia, central or overall obesity, microalbuminuria. The syndrome was initially described with insulin resistance as the central element [2]. We have as yet no evidence to believe otherwise. The syndrome, as de®ned by the WHO, requires a clamp study to be performed. As this de®nition is going to be used mainly in epidemiology, and may in the future be used in clinical practice, it is essential that readily available measures are used. Given the relatively high negative correlation in nondiabetic subjects between fasting insulin and insulin sensitivity as measured in clamp studies [3], insulin resistant individuals could be de®ned as the 25% of the population with the highest insulin resistance or the highest fasting insulin concentrations, providing the population under study could be thought to be representative of the nondiabetic population. Fasting insulin is so far the best available simple proxy for insulin resistance but it could be replaced in the future by other simple measurement(s) correlated with insulin resistance. As there are different standards for assaying insulin, it is not possible to propose a universal cut-off. If in future studies, this de®nition is found to be useful in clinical practice, the standardization of insulin assays will be mandatory. The de®nition we propose is for nondiabetic individuals only because there is no simple way to measure insulin resistance in diabetic individuals. We suggest the syndrome is de®ned by the presence of insulin resistance or fasting hyperinsulinaemia (the highest 25%) and two of hyperglycaemia (fasting plasma glucose > 6.1 mmol/l, but nondiabetic); hypertension (systolic/diastolic blood pressures > 140/ 90 mmHg or treated for hypertension); dyslipidaemia (triglycerides > 2.0 mmol/l or HDL-cholesterol < 1.0 mmol/l or treated for dyslipidaemia); central obesity (waist circumference > 94 cm in men and > 80 cm in women). All of these criteria must be measured before it is possible to evaluate the presence of the syndrome. Hyperglycaemia should be de®ned at fasting (fasting plasma glucose > 6.1 mmol/l or impaired fasting glucose) in nondiabetic individuals. Only the fasting criteria are suggested to provide simpler criteria. The recent report from the Second Joint Task Force of European and other Societies on Coronary Prevention [4] refer to systolic/diastolic blood pressures of 140/90 mmHg as being mild. The same report commented that fasting triglycerides > 2.0 mmol/l (180 mg/dl) and/or a HDL-cholesterol < 1.0 mmol/l (40 mg/dl) were `markers of increased coronary heart disease risk'. For central obesity the proposed criteria used the waist-tohip ratio. The waist circumference is to be preferred as it is simpler to measure and better correlated with intra-abdominal visceral adipose tissue accumulation [5]. A recent study provides cut-off values of 94 cm for men and 80 cm for women as `action levels' for prevention [6]. These limits could be used pending further research in this area [7]. Overall obesity, as measured by the body mass index, has not generally been considered to be part of the syndrome and for that reason it should be omitted. For microalbuminuria, it has not been universally shown to be linked with insulin concentrations [8,9], although a recent article showed it to be linked to insulin resistance [10]. Microalbuminuria is not `necessary for the recognition of the condition' as stated by the WHO document and should be omitted from the de®nition of the syndrome. The ®nal statement of the WHO consultation was that other components `have been described (e.g. hyperuricaemia, coagulationdisorders, raisedPAI-1)but that theyarenotnecessary fortherecognitionofthecondition'.Forpracticalpurposes,and so that the syndrome can be described in most epidemiological studies and can be useful in identifying individuals at risk, it should include a minimum number of components. As this de®nition is simple, it could be used in most epidemiological studies; it would at long last enable comparisons between studies, of the frequency and of the risk associated with the insulin resistance syndrome. read more

Topics:

Insulin resistance (52%)52% related to the paper

1,821 Citations

Journal Article • DOI: 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I •

The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

A.F. Amos, D.J. McCarty,

01 Dec 1997 - Diabetic Medicine

Abstract:

Prevention and control programmes are needed to stem the rising epidemic of diabetes and its complications. However, these will not occur unless governments and public health planners are aware of the potential problem. Using published prevalence rates for NIDDM in different populations, and the current and projected age dist... Prevention and control programmes are needed to stem the rising epidemic of diabetes and its complications. However, these will not occur unless governments and public health planners are aware of the potential problem. Using published prevalence rates for NIDDM in different populations, and the current and projected age distributions, worldwide prevalence of NIDDM was estimated for 1995 and 1997, and well as projections for 2000 and 2010. Prevalence rates used for projections were chosen to reflect changes in lifestyle with economic development. The global prevalence of IDDM was estimated using published incidence rates and population figures, incorporating the likely survival time from development of IDDM. Data on diabetes complications are also summarised but no attempt has been made to extrapolate to a global estimated. In 1997, an estimated 124 million people worldwide have diabetes, 97% of these having NIDDM. By the year 2010 the total number of people with diabetes is projected to reach 221 million. The regions with the greatest potential increases are Asia and Africa, where diabetes rates could rise to 2 or 3 times those experienced today. With improvements in the treatment of IDDM, the prevalence of this form of diabetes is likely to increase as more people survive for longer after diagnosis. Increases in complications will undoubtedly follow increasing prevalence of diabetes, but population-based studies using standardised methods of diagnosis are required before reliable estimates of the extent of the problem can be made. It is hoped that the information provided in this report, and others like it, will act as an incentive to initiate or improve local diabetes monitoring and prevention strategies. read more

Topics:

Population (53%)53% related to the paper, Global health (52%)52% related to the paper

1,746 Citations

Journal Article • DOI: 10.1111/J.1464-5491.2006.01943.X •

The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis

S. Ali¹, Margaret A. Stone¹, •

01 Nov 2006 - Diabetic Medicine

Abstract:

Aim To conduct a systematic literature review in order to estimate the prevalence and odds ratio of clinically relevant depression in adults with Type 2 diabetes compared with those without. Methods medline, embase and psycinfo databases were searched using MeSH terms and free text to identify relevant controlled studies. ... Aim To conduct a systematic literature review in order to estimate the prevalence and odds ratio of clinically relevant depression in adults with Type 2 diabetes compared with those without. Methods medline, embase and psycinfo databases were searched using MeSH terms and free text to identify relevant controlled studies. Published reference lists were also examined. Study selection and appraisal were conducted independently by two reviewers and a meta-analysis was performed to synthesize and analyse the data. Results Ten controlled studies including a total of 51 331 people were published between January 1980 and May 2005. The prevalence of depression was significantly higher in patients with Type 2 diabetes compared with those without [17.6 vs. 9.8%, OR = 1.6, 95%, confidence interval (CI) 1.2–2.0]. However, in most studies, patients with diabetes differed from those without on variables known to be associated with an increased risk of depression. The prevalence of depression was higher in females with diabetes (23.8%) compared with males (12.8%); however, the odds ratio for depression in patients with Type 2 diabetes compared with those without was higher in males (OR = 1.9, 95% CI 1.7–2.1) than females (OR = 1.3, 95% CI 1.2–1.4). Failure to report potential confounders prevented a more rigorous meta-analysis of risk. Conclusion We identified raised rates of depression in people with Type 2 diabetes, however, there is a need for well-controlled and better-reported studies to inform the development of effective treatments for depression in these patients. read more

Topics:

Depression (differential diagnoses) (54%)54% related to the paper, Odds ratio (54%)54% related to the paper, Type 2 diabetes (51%)51% related to the paper,

1,101 Citations

Also popular among researchers

“

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds

Choose a template

Select a template from a library of 40,000+ templates

Import a MS-Word file or start fresh

It takes only few seconds to import

View and edit your final output

SciSpace will automatically format your output to meet journal guidelines

Submit directly or Download

Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

With SciSpace, you do not need a word template for Diabetic Medicine.

It automatically formats your research paper to Wiley formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

Easy support from all your favorite tools

Diabetic Medicine format uses apa citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Diabetic Medicine in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Diabetic Medicine guidelines and auto format it.

2. Do you follow the Diabetic Medicine guidelines?

Yes, the template is compliant with the Diabetic Medicine guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Diabetic Medicine?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Diabetic Medicine citation style.

4. Can I use the Diabetic Medicine templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Diabetic Medicine.

5. Can I use a manuscript in Diabetic Medicine that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Diabetic Medicine that you can download at the end.

6. How long does it usually take you to format my papers in Diabetic Medicine?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Diabetic Medicine.

7. Where can I find the template for the Diabetic Medicine?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Diabetic Medicine's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Diabetic Medicine's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Diabetic Medicine an online tool or is there a desktop version?

SciSpace's Diabetic Medicine is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Diabetic Medicine?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Diabetic Medicine?”

11. What is the output that I would get after using Diabetic Medicine?

After writing your paper autoformatting in Diabetic Medicine, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Diabetic Medicine's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Diabetic Medicine?

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Diabetic Medicine. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour	Archiving policy
Green	Can archive pre-print and post-print or publisher's version/PDF
Blue	Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow	Can archive pre-print (ie pre-refereeing)
White	Archiving not formally supported

FYI:

Pre-prints as being the version of the paper before peer review and
Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Diabetic Medicine?

The 5 most common citation types in order of usage for Diabetic Medicine are:.

S. No.	Citation Style Type
1.	Author Year
2.	Numbered
3.	Numbered (Superscripted)
4.	Author Year (Cited Pages)
5.	Footnote

15. How do I submit my article to the Diabetic Medicine?

16. Can I download Diabetic Medicine in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Diabetic Medicine Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Diabetic Medicine formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

“

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

”

Andreas Frutiger
Researcher & Ex MS Word user

Diabetic Medicine — Template for authors

Related Journals

Journal Performance & Insights

Impact Factor

CiteRatio

3.083

6.1

Insights

Insights

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

1.474

1.473

Insights

Insights

Diabetic Medicine

Top papers written in this journal

Abstract:

Topics:

Abstract:

Abstract:

Topics:

Abstract:

Topics:

Abstract:

Topics:

What to expect from SciSpace?

Speed and accuracy over MS Word

Plagiarism Reports via Turnitin

Freedom from formatting guidelines

Easy support from all your favorite tools

Frequently asked questions

Fast and reliable, built for complaince.

No word template required

Verifed journal formats

Trusted by academicians

Fast and reliable,
built for complaince.